The new product is a ready-to-use, injectable bone matrix in paste form, consisting of 100 percent synthetic, non-particular, phase-pure hydroxylapatite. It can be used during orthopedic, trauma and neurosurgery procedures to fill and reconstruct bone defects or in conjunction with allograft and autograft as bone graft extender.
More Articles on Orthopedic Devices:
FDA Sends Warning Letters to California Orthopedic & Spine Device Companies
FDA Publishes Guidance for Pre-market Approvals
Wright Medical Group Names James Lightman Senior Vice President
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.